New stock news | Ko Li Holdings Limited submitted application to Hong Kong Stock Exchange

According to the disclosure of the Hong Kong Stock Exchange on December 18, Ke Li Limited has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. The prospectus shows that Ke Li is a comprehensive medical health solution provider originating from South Korea, with its main business located in China and expanding its international business scope. According to Frost & Sullivan data, based on 2024 revenue, the company ranks in the top ten in the marketing, promotion and sales market of China Meheco Group. Based on 2024 revenue, the company is the largest pediatric pharmaceutical marketing, promotion and sales service provider in China, accounting for approximately 15.9% of the market share in China. The company is committed to promoting the upgrade of the pharmaceutical supply chain through digital solutions, while promoting innovation in the fields of biohealth and functional nutrition. During the reporting period, the company primarily engaged in the following business lines: pharmaceutical marketing, promotion and sales business; research, production and distribution of maternal and child health products and nutritional supplements.